Compare iShares MSCI India ETF (INDA) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs Viatris Inc — how do they compare? iShares MSCI India ETF trades at $48.2, while Viatris Inc trades at $17.05 (market cap $20.50B). The key difference: Viatris Inc pays a 2.73% dividend while iShares MSCI India ETF pays none, and Viatris Inc is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.
| INDA | VTRS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $17.59 |
52-Week Low | $45.42 | $8.74 |
Market Cap | — | $20.50B |
Enterprise Value | — | $32.71B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA, the iShares MSCI India ETF, trades at $48.56, down 0.72% on the day. The technical outlook is bearish, with moving averages indicating selling pressure and oscillators neutral. Recent news highlights India's strong economic growth at 7.8% for Q1 2026 (CNBC, 2026-06-05) but notes headwinds including muted IT sector performance and geopolitical risks from the Middle East.
The ETF offers exposure to India's fast-growing economy but faces near-term risks from sector-specific challenges and external volatility. Analyst sentiment is mixed, with some seeing value in the long-term growth story despite recent underperformance versus other emerging markets.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
